CN106661030B - 用于药物制剂中的PI3K δ选择性抑制剂的改良形式 - Google Patents

用于药物制剂中的PI3K δ选择性抑制剂的改良形式 Download PDF

Info

Publication number
CN106661030B
CN106661030B CN201580034288.7A CN201580034288A CN106661030B CN 106661030 B CN106661030 B CN 106661030B CN 201580034288 A CN201580034288 A CN 201580034288A CN 106661030 B CN106661030 B CN 106661030B
Authority
CN
China
Prior art keywords
salt
disease
tgr
ptsa salt
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580034288.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106661030A (zh
Inventor
斯瓦鲁普·库马尔·文卡塔·萨蒂亚·瓦卡拉恩卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhizen Pharmaceuticals AG
Original Assignee
Rhizen Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals AG filed Critical Rhizen Pharmaceuticals AG
Priority to CN202010471226.5A priority Critical patent/CN111635406A/zh
Publication of CN106661030A publication Critical patent/CN106661030A/zh
Application granted granted Critical
Publication of CN106661030B publication Critical patent/CN106661030B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580034288.7A 2014-05-27 2015-05-26 用于药物制剂中的PI3K δ选择性抑制剂的改良形式 Expired - Fee Related CN106661030B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010471226.5A CN111635406A (zh) 2014-05-27 2015-05-26 用于药物制剂中的PI3Kδ选择性抑制剂的改良形式

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2596/CHE/2014 2014-05-27
IN2596CH2014 2014-05-27
IN2597CH2014 2014-05-27
IN2597/CHE/2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010471226.5A Division CN111635406A (zh) 2014-05-27 2015-05-26 用于药物制剂中的PI3Kδ选择性抑制剂的改良形式

Publications (2)

Publication Number Publication Date
CN106661030A CN106661030A (zh) 2017-05-10
CN106661030B true CN106661030B (zh) 2020-06-30

Family

ID=53499042

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580034288.7A Expired - Fee Related CN106661030B (zh) 2014-05-27 2015-05-26 用于药物制剂中的PI3K δ选择性抑制剂的改良形式
CN202010471226.5A Pending CN111635406A (zh) 2014-05-27 2015-05-26 用于药物制剂中的PI3Kδ选择性抑制剂的改良形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010471226.5A Pending CN111635406A (zh) 2014-05-27 2015-05-26 用于药物制剂中的PI3Kδ选择性抑制剂的改良形式

Country Status (22)

Country Link
US (4) US9969740B2 (enExample)
EP (2) EP3149000B1 (enExample)
JP (3) JP6987501B2 (enExample)
KR (1) KR20170007480A (enExample)
CN (2) CN106661030B (enExample)
AU (1) AU2015265542B2 (enExample)
BR (1) BR112016027674A2 (enExample)
CA (1) CA2949932C (enExample)
CY (1) CY1124316T1 (enExample)
DK (1) DK3149000T3 (enExample)
EA (1) EA032506B1 (enExample)
ES (1) ES2880999T3 (enExample)
HR (1) HRP20211151T1 (enExample)
HU (1) HUE054916T2 (enExample)
IL (1) IL249058B2 (enExample)
LT (1) LT3149000T (enExample)
PL (1) PL3149000T3 (enExample)
PT (1) PT3149000T (enExample)
RS (1) RS62136B1 (enExample)
SI (1) SI3149000T1 (enExample)
SM (1) SMT202100532T1 (enExample)
WO (1) WO2015181728A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100532T1 (it) * 2014-05-27 2021-11-12 Rhizen Pharmaceuticals S A Sale tosilato cristallino di un inibitore 5 selettivo di pi3k delta per l’uso in formulazioni farmaceutiche
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders
US20190247399A1 (en) 2016-09-09 2019-08-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
WO2021009509A1 (en) 2019-07-15 2021-01-21 Johnson Matthey Public Limited Company Amorphous umbralisib monotosylate
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440408A (zh) * 2000-04-25 2003-09-03 艾科斯有限公司 人磷脂酰肌醇3－激酶δ的抑制剂
WO2014006572A1 (en) * 2012-07-04 2014-01-09 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
JP5794919B2 (ja) 2008-11-13 2015-10-14 ギリアード カリストガ エルエルシー 血液学的な悪性疾患のための療法
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
SG175259A1 (en) 2009-04-20 2011-11-28 Gilead Calistoga Llc Methods of treatment for solid tumors
SMT202100532T1 (it) * 2014-05-27 2021-11-12 Rhizen Pharmaceuticals S A Sale tosilato cristallino di un inibitore 5 selettivo di pi3k delta per l’uso in formulazioni farmaceutiche

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440408A (zh) * 2000-04-25 2003-09-03 艾科斯有限公司 人磷脂酰肌醇3－激酶δ的抑制剂
WO2014006572A1 (en) * 2012-07-04 2014-01-09 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors

Also Published As

Publication number Publication date
IL249058B2 (en) 2023-03-01
EP3149000A1 (en) 2017-04-05
PL3149000T3 (pl) 2021-11-02
BR112016027674A2 (pt) 2017-08-15
AU2015265542B2 (en) 2019-05-09
RS62136B1 (sr) 2021-08-31
KR20170007480A (ko) 2017-01-18
AU2015265542A1 (en) 2016-12-08
US20170121336A1 (en) 2017-05-04
US20190016725A1 (en) 2019-01-17
DK3149000T3 (da) 2021-08-30
ES2880999T3 (es) 2021-11-26
JP2020122022A (ja) 2020-08-13
US9969740B2 (en) 2018-05-15
US20190382411A1 (en) 2019-12-19
LT3149000T (lt) 2021-09-10
HUE054916T2 (hu) 2021-10-28
US20210269446A1 (en) 2021-09-02
WO2015181728A1 (en) 2015-12-03
IL249058A0 (en) 2017-01-31
JP2017516785A (ja) 2017-06-22
IL249058B (en) 2022-11-01
JP6987501B2 (ja) 2022-01-05
EA201692255A1 (ru) 2017-04-28
CY1124316T1 (el) 2022-07-22
PT3149000T (pt) 2021-07-27
SI3149000T1 (sl) 2021-09-30
SMT202100532T1 (it) 2021-11-12
US10414773B2 (en) 2019-09-17
EP3149000B1 (en) 2021-06-30
CA2949932C (en) 2021-08-10
JP2022082680A (ja) 2022-06-02
HRP20211151T1 (hr) 2021-10-15
EA032506B1 (ru) 2019-06-28
CN111635406A (zh) 2020-09-08
CA2949932A1 (en) 2015-12-03
US10947244B2 (en) 2021-03-16
CN106661030A (zh) 2017-05-10
EP3971188A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
CN106661030B (zh) 用于药物制剂中的PI3K δ选择性抑制剂的改良形式
JP7291839B2 (ja) 固体形態のｃｄｋ４阻害薬
JP2020528884A (ja) キナーゼを調節する化合物の製剤
CN110913861B (zh) G1t38的形态学形式及其制造方法
CN116615426A (zh) Fgfr抑制剂和其制造和使用方法
TW202131930A (zh) 抗癌核荷爾蒙受體標靶化合物
JP2025503139A (ja) 固形腫瘍の治療のためのユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤
TW202108570A (zh) 抗癌核荷爾蒙受體標靶化合物
HK1236026B (en) Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations
EA042667B1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
HK40087859A (zh) Cdk4抑制剂的固体形式
CN118660884A (zh) Cft7455的晶型物及其制造方法
BR112019027967B1 (pt) Forma b cristalina isolada, composição farmacêutica, uso de um composto ou composição, e, processo para produzir forma b cristalina
CN1990462A (zh) 琥珀酰肼类化合物及其组合物在制备治疗抗白血病药物方面的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200630

CF01 Termination of patent right due to non-payment of annual fee